Experience

• 

  Biogen

  • United States
  • Biotechnology Research
  • 700 & Above Employee

  • VP, Global Commercial Strategy

    • Jan 2013 - Feb 2015

    Led global commercial strategy team responsible for integrating commercial vision with innovative science to bring life-changing therapies to patients. • Developed and directed commercial strategy for all assets in pipeline. Ensured clinical development plans were designed to optimize differentiation and future labeling.• Responsible for the launch preparations, global marketing, and life cycle management of all specialty products (e.g., ELOCTATE® and ALPROLIX® for hemophilia).• Provided commercial leadership and due diligence for Business Development and Merger & Acquisition opportunities. • Created strategies to operationalize corporate vision. Prioritized focus areas and target diseases, developed target treatment concepts, determined minimal target profiles with supporting analytics/valuation.• Aligned commercial leadership on strategic recommendations to Executive Committee and Board of Directors.

  • VP, US Marketing

    • Oct 2010 - Jan 2013

    Led US marketing team, growing MS revenue from $2B to $6B and market share from 30% to nearly 50%. Delivered P&L successes for AVONEX® and TYSABRI® despite a fiercely competitive landscape and innovative market entrants. Directed launch of TECFIDERA® and prepared for launch of Dexpramipexole. Managed 74 marketing professionals divided across four brand teams, a patient and professional advocacy team (including 15 field-based), an emerging portfolio team, and an operations group responsible for production/fulfillment. • Reversed multi-year decline in AVONEX revenue, driving growth in demand and market share despite maturity (16 years old) and the launch of oral competitors. Delivered sustained revenue/share growth not seen since 1999. • Optimized TYSABRI value with risk stratification strategy supported by commercialization of a JCV assay biomarker.• Prepared all aspects of TECFIDERA® launch, including segmentation, positioning, messaging, core campaign, sales infrastructure/targeting, channel strategy, value proposition/pricing, web and digital display, packaging, promotional programming. Analysts called it “the mother of all launches”, with US revenue at $3B in two years.• Led development of Dexpramipexole launch plan, including early access program, 3rd party advocacy, and all elements of market entry strategy.

• 

  Johnson & Johnson

  • Executive Director / Global Marketing Leader

    • Jan 2000 - Oct 2010

    Led global team responsible for the commercial strategy, launch readiness, and life cycle planning for SIMPONI® (golimumab), an anti-TNF biologic expected to deliver revenue in excess of $1 billion. Launched three rheumatology indications and a patented auto-injector in 2009; built growth initiatives and mitigation strategies to support rheumatology platform. Developed commercial strategies for ulcerative colitis, IV administration, and additional novel indications. • Led cross-functional commercial team with membership from in-line country marketing, global strategic marketing, market research, global strategic analytics, global medical affairs, and R&D to develop and execute the global commercial strategy.– Set the vision and gained commitment from key stakeholders and constituent groups. Enlisted support for vision via leadership, influence, negotiation with internal partners.• Partnered with R&D to design studies and labeling that supported commercial strategies.• Ensured global launch readiness, including: segmentation and positioning (professional / patient / payor), core message platform, global branding, publications and data display, pricing and reimbursement plan, sales/marketing infrastructure, optimized product labeling, packaging, supply chain, and risk mitigation.• Delivered presentations on global commercial strategies and launch readiness to senior management, operations management, and executive officers.• Managed partnerships with Merck and Mitsubishi Tanabe for co-promotions in EU and Japan.• Selected, developed and retained superior talent.• Recipient of two Standards of Leadership awards. 1/03 to 9/06 Exec Director - Global Marketing Leader/Executive Director, COMFYDE®, CNS, Raritan, NJ 1/00 – 12/02 Director - Global Commercial Leader/Director, TOPAMAX®, CNS & Metabolic, Raritan, NJ

• 

  GSK

  • Collegeville, PA

  • Associate Director

    • Apr 1997 - Jan 2000
    • Collegeville, PA

    Responsible for pre-launch preparation and the subsequent worldwide launch of AVANDIA® (rosiglitazone), a blockbuster oral agent for the treatment of type 2 diabetes. • Developed a three-year strategic plan; obtained senior management endorsement and presented the plan to core markets in North America, Europe and Asia.• Planned and directed marketing programs, including: advisory boards, congress exhibits and symposia, public relations campaigns, an opinion leader registry, and speaker advocacy programs. • Planned and executed a publications strategy that produced 57 manuscripts and 143 abstracts/posters over two years. Chaired a multi-disciplinary publication strategy team. • Championed commercial needs into clinical trial protocol development and target labeling. Educated senior management on key issues and opportunities at monthly briefings. • Created a product resources database heralded as a new "best practice" company standard. • Supported business development initiatives as a task force member assigned to evaluate in-licensing opportunities, product line extensions, and potential strategic alliances. • Managed marketing budget of $7.5 million. Supervised two direct reports, two communications managers, and external agencies. Recipient of five Awards of Excellence.

• 

  Sanofi

  • Collegeville, PA

  • Senior Brand Manager

    • Dec 1991 - Apr 1997
    • Collegeville, PA

    Factor VIII Products – MONOCLATE-P®, HELIXATE®, BIOCLATE®, HUMATE®Responsible for the development of in-line marketing plans, demand forecasting to drive manufacturing, competitor tracking, and pricing strategies. Directed CME symposia, publication strategies, speaker advocate programs, physician/patient education, physician advisory panels, and sales training. Supervised staff of two. • Product sales of >$200 million grew at a five-year compounded annual growth rate of 11% compared with a marketplace compounded annual growth rate of 6%.• Market leader for each brand, despite premium pricing of 10% to 30% over nearest competitor.• Overall market growth of 20% attributable to aggressive leadership and education on prophylaxis and immune tolerance protocols as a new standard of care for hemophilia.1/93 – 6/95 Global Product Manager, Hemophilia B Therapy, MONONINE®Launched MONONINE in North America, South America, Europe and Taiwan. Responsible for strategic allocation of global product inventories during periods when worldwide market demand exceeded manufacturing capacity. Supervised one. • Established MONONINE as the sales, market share, and price leader in each market.• Grew US market share to 60% in three years despite a 33% price premium.12/91 – 1/93 Associate Product Manager, Hemophilia Inhibitor Therapy, HYATE:C